Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model.
The effects of the soybean isoflavone genistein and a commercially-available isoflavone-containing soy extract on the growth of F3II mouse mammary adenocarcinoma cells were investigated. Female Balb/c mice injected (s.c.) with F3II cells and fed diets supplemented with 0.6% soy extract (containing genistein at 750 ppm) exhibited a significant 90% reduction in tumor weight compared to controls, whereas female mice fed diets supplemented with 750 ppm genistein alone exhibited a significant 40% reduction in tumor weight compared to controls. Tumor samples from animals fed the 0.6% soy extract, but not from those animals fed the 750 ppm genistein diet alone, exhibited significantly higher protein levels of the cyclin-dependent kinase inhibitor p21(waf1/cip1) compared to controls. Neither of the two experimental diets altered tumor estrogen receptor-alpha or progesterone receptor protein levels. In vitro, genistein significantly inhibited F3II cell proliferation (IC(50) approximately 2-3 microM) and caused a G2/M block in cell cycle progression at concentrations as low as 5 microM. This genistein-induced G2/M arrest in vitro was associated with a significant increase in the protein expression of phosphorylated p34(cdc2) and of cyclin B1. These results indicate that genistein is an inhibitor of F3II mouse mammary adenocarcinoma cell growth in vivo and in vitro, in part due to its effect on specific cell cycle regulatory proteins. In addition, genistein fed to mice as part of the soy extract resulted in a greater magnitude of inhibition of mouse mammary adenocarcinoma tumor growth, compared to tumor growth of animals fed an equivalent amount of genistein alone. This suggests that genistein along with other constituent(s) in the soy extract may also contribute to suppression of F3II tumor growth.
Hewitt
Amy L
AL
Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, IL 61801, USA.
Singletary
Keith W
KW
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D019833:Genistein / Q000494:pharmacology / Q000627:therapeutic use; D007529:Isoflavones / Q000494:pharmacology* / Q000627:therapeutic use*; D051379:Mice; D009361:Neoplasm Invasiveness; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use*; D013025:Glycine max / Q000737:chemistry*
D018797:Cell Cycle Proteins; D007529:Isoflavones; D010936:Plant Extracts; C004742:daidzein; D019833:Genistein